z-logo
open-access-imgOpen Access
Mucosal Eosinophilia Is an Independent Predictor of Vedolizumab Efficacy in Inflammatory Bowel Diseases
Author(s) -
Erin M. Kim,
Cara Randall,
Renée Betancourt,
Staci Keene,
Amy Lilly,
Mark R. Fowler,
Evan S. Dellon,
Hans Herfarth
Publication year - 2019
Publication title -
inflammatory bowel diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.932
H-Index - 146
eISSN - 1536-4844
pISSN - 1078-0998
DOI - 10.1093/ibd/izz251
Subject(s) - vedolizumab , medicine , eosinophil , gastroenterology , ulcerative colitis , eosinophilia , inflammatory bowel disease , immunology , disease , asthma
Peripheral and mucosal eosinophilia may be associated with more aggressive disease in inflammatory bowel disease (IBD) patients. Vedolizumab blocks T lymphocytes, eosinophil adhesion, and extravasation in the gastrointestinal tract. It is not known if mucosal eosinophilia is a predictor for the therapeutic efficacy of vedolizumab.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here